1372 related articles for article (PubMed ID: 24449821)
1. Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy.
Tersteeg C; de Maat S; De Meyer SF; Smeets MW; Barendrecht AD; Roest M; Pasterkamp G; Fijnheer R; Vanhoorelbeke K; de Groot PG; Maas C
Circulation; 2014 Mar; 129(12):1320-31. PubMed ID: 24449821
[TBL] [Abstract][Full Text] [Related]
2. Degradation of platelet-von Willebrand factor complexes by plasmin: an alternative/backup mechanism to ADAMTS13.
Chauhan AK
Circulation; 2014 Mar; 129(12):1273-5. PubMed ID: 24449820
[No Abstract] [Full Text] [Related]
3. Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosis.
El Otmani H; Frunt R; Smits S; Barendrecht AD; de Maat S; Fijnheer R; Lenting PJ; Tersteeg C
Blood; 2024 May; 143(20):2089-2098. PubMed ID: 38271661
[TBL] [Abstract][Full Text] [Related]
4. Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis.
de Maat S; Clark CC; Barendrecht AD; Smits S; van Kleef ND; El Otmani H; Waning M; van Moorsel M; Szardenings M; Delaroque N; Vercruysse K; Urbanus RT; Sebastian S; Lenting PJ; Hagemeyer CE; Renné T; Vanhoorelbeke K; Tersteeg C; Maas C
Blood; 2022 Jan; 139(4):597-607. PubMed ID: 34752601
[TBL] [Abstract][Full Text] [Related]
5. Proteolytic inactivation of ADAMTS13 by plasmin in human plasma: risk of thrombotic thrombocytopenic purpura.
Shin Y; Miyake H; Togashi K; Hiratsuka R; Endou-Ohnishi K; Imamura Y
J Biochem; 2018 May; 163(5):381-389. PubMed ID: 29228282
[TBL] [Abstract][Full Text] [Related]
6. Response to letter regarding article, "plasmin cleavage of von willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy".
Tersteeg C; de Maat S; De Meyer SF; Smeets MW; Barendrecht AD; Roest M; Pasterkamp G; Fijnheer R; Vanhoorelbeke K; de Groot PG; Maas C
Circulation; 2015 Jan; 131(2):e19-20. PubMed ID: 25583061
[No Abstract] [Full Text] [Related]
7. Letter by Hugenholtz and Lisman regarding article, "plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy".
Hugenholtz GC; Lisman T
Circulation; 2015 Jan; 131(2):e18. PubMed ID: 25583060
[No Abstract] [Full Text] [Related]
8. Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice.
Tersteeg C; Joly BS; Gils A; Lijnen R; Deckmyn H; Declerck PJ; Plaimauer B; Coppo P; Veyradier A; Maas C; De Meyer SF; Vanhoorelbeke K
J Thromb Haemost; 2017 Dec; 15(12):2432-2442. PubMed ID: 28981198
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in thrombotic thrombocytopenic purpura.
Sadler JE; Moake JL; Miyata T; George JN
Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
[TBL] [Abstract][Full Text] [Related]
10. [ADAMTS13-Mediated Proteolytic Cleavage of Unusually Large von Willebrand Factor Polymers on Endothelial Cells in the Absence of Fluid Shear Stress].
Zhao SC; Li H; Wang M; Zhao YH; Li XJ; Jin SY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):532-540. PubMed ID: 38660863
[TBL] [Abstract][Full Text] [Related]
11. [ADAMTS13, von Willebrand factor specific cleaving protease].
Veyradier A; Coppo P
Med Sci (Paris); 2011 Dec; 27(12):1097-105. PubMed ID: 22192749
[TBL] [Abstract][Full Text] [Related]
12. Plasmin Cleaves Von Willebrand Factor at K1491-R1492 in the A1-A2 Linker Region in a Shear- and Glycan-Dependent Manner In Vitro.
Brophy TM; Ward SE; McGimsey TR; Schneppenheim S; Drakeford C; O'Sullivan JM; Chion A; Budde U; O'Donnell JS
Arterioscler Thromb Vasc Biol; 2017 May; 37(5):845-855. PubMed ID: 28279966
[TBL] [Abstract][Full Text] [Related]
13. The potential therapeutic benefit of targeting ADAMTS13 activity.
Eerenberg ES; Levi M
Semin Thromb Hemost; 2014 Feb; 40(1):28-33. PubMed ID: 24338607
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of thrombotic thrombocytopenic purpura: ADAMTS13 deficiency and beyond.
Lian EC
Semin Thromb Hemost; 2005 Dec; 31(6):625-32. PubMed ID: 16388413
[TBL] [Abstract][Full Text] [Related]
15. A role for tissue plasminogen activator in thrombotic thrombocytopenic purpura.
Hoirisch-Clapauch S; Nardi AE
Med Hypotheses; 2014 Dec; 83(6):747-50. PubMed ID: 25459148
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of ADAMTS13 by plasmin as a potential cause of thrombotic thrombocytopenic purpura.
Feys HB; Vandeputte N; Palla R; Peyvandi F; Peerlinck K; Deckmyn H; Lijnen HR; Vanhoorelbeke K
J Thromb Haemost; 2010 Sep; 8(9):2053-62. PubMed ID: 20553378
[TBL] [Abstract][Full Text] [Related]
17. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
Kato S; Fujimura Y
Rinsho Byori; 2015 Oct; 63(10):1228-36. PubMed ID: 26897861
[TBL] [Abstract][Full Text] [Related]
18. Keeping von Willebrand Factor under Control: Alternatives for ADAMTS13.
Tersteeg C; Fijnheer R; Pasterkamp G; de Groot PG; Vanhoorelbeke K; de Maat S; Maas C
Semin Thromb Hemost; 2016 Feb; 42(1):9-17. PubMed ID: 26595154
[TBL] [Abstract][Full Text] [Related]
19. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura.
Tersteeg C; Schiviz A; De Meyer SF; Plaimauer B; Scheiflinger F; Rottensteiner H; Vanhoorelbeke K
Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2336-42. PubMed ID: 26338302
[TBL] [Abstract][Full Text] [Related]
20. Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.
Budde U; Schneppenheim R
Hamostaseologie; 2014; 34(3):215-25. PubMed ID: 25010251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
